Article

Pharmaceutical Technology Europe

Pharmaceutical Technology Europe

Pharmaceutical Technology Europe-01-01-2003
Volume15
Issue 1

Is drug delivery the enemy of drug research?

Author(s):

Albedo

Brussels report

The European drug industry's dilemma gets no easier - drugs must be discovered before they can be delivered. However, the pharmaceutical sector's reluctance to pay for delivery still threatens to deprive the industry of the revenue to do its research.

This article is currently available in printed form only.
 To ensure access to all articles from every issue of Pharmaceutical Technology Europesubscribe here now.

Articles in this issue
Taking the Industry's Pulse: Fifth Annual International Employment Survey
Taking the Industry's Pulse: Fifth Annual International Employment Survey
Taking the Industry's Pulse: Fifth Annual International Employment Survey
Taking the Industry's Pulse: Fifth Annual International Employment Survey
Is drug delivery the enemy of drug research?
Improving Dose Content Uniformity Testing for MDIs and DPIs
Improving Dose Content Uniformity Testing for MDIs and DPIs
Innovations in Pharmaceutical Packaging - Smart Blister Packs
Innovations in Pharmaceutical Packaging - Smart Blister Packs
chart1-52363-1408718626367.gif
Pharmaceutical Pricing and Innovation: Key Issues in the Year Ahead
PS 9100:2002 Pharmaceutical Excipients - An Updated GMP Standard for Excipients Suppliers
PS 9100:2002 Pharmaceutical Excipients - An Updated GMP Standard for Excipients Suppliers

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Behind the Headlines, Episode 18
Related Content
White House | Image Credit: © Zack Frank - stock.adobe.com
August 2nd 2025

Trump Sends Letters to 17 Leading Pharma Companies Outlining Most-Favored-Nation Drug Pricing Protocol

Patrick Lavery
If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 2nd 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Kratom or Mitragyna speciosa on natural background. | Image Credit: © wasanajai - stock.adobe.com
August 2nd 2025

FDA Seeks Scheduling Action to Control Harmful Kratom Plant Byproduct

Patrick Lavery
7-OH and the leaf of the kratom plant are not analogous, but as the former is a derivative of the latter, it has opioid-like qualities that make its susceptibility to abuse concerning.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 2nd 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
automatic stainless steel pharmaceutical fermenter | Image Credit: ©gen_A - stock.adobe.com
August 2nd 2025

In-line UV Spectrometry Monitoring in Cleaning Validation

John Schallom Brian Bosso Paul Lopolito Katie Frey Amy Thanavaro
The authors performed interference and enhancement testing using a formulated alkaline and acid cleaner, as well as common biopharmaceutical process residues.
woman face and hand with syringe making injection | Image Credit: © Syda Productions - stock.adobe.com
August 2nd 2025

Boehringer Ingelheim, Re-Vana Therapeutics to Collaborate on Long-Acting Ophthalmic Therapies

Patrick Lavery
Re-Vana’s drug delivery technology is designed to release treatments over a 6- to 12-month period, with the goal of reducing frequency of injections for patients.